NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
211 Östergötland

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 46 0.7% 39 0.6% 5 0.1% 1 0.0% . . 1 0.0% 6977 98.7% 7069 100.0%
ASCUS 88 11.7% 208 27.7% 80 10.7% . . . . 3 0.4% 371 49.5% 750 100.0%
LSIL 23 6.0% 108 28.2% 67 17.5% 2 0.5% 1 0.3% 2 0.5% 180 47.0% 383 100.0%
Atypical glandular cells/AGC . . 1 12.5% 2 25.0% 3 37.5% 1 12.5% . . 1 12.5% 8 100.0%
Unclear atypia . . 1 100.0% . . . . . . . . . . 1 100.0%
ASC-H 2 4.8% 8 19.0% 31 73.8% 1 2.4% . . . . . . 42 100.0%
HSIL 1 0.8% 13 10.2% 103 81.1% 4 3.1% 4 3.1% . . 2 1.6% 127 100.0%
Suspected Adenocarcinom . . . . . . 2 66.7% 1 33.3% . . . . 3 100.0%
Squamous cell cancer . . . . 1 50.0% . . 1 50.0% . . . . 2 100.0%
Totalt 160 1.9% 378 4.5% 289 3.4% 13 0.2% 8 0.1% 6 0.1% 7531 89.8% 8385 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the
category Cancer:
M80703, M81403